Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
(Values in thousands)
| 10-2025 | 07-2025 | 04-2025 | 01-2025 | 10-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 498 | 65 | 715 | 1,996 | 228 |
| Receivables | 177 | 121 | 287 | 236 | 176 |
| TOTAL | $675 | $409 | $1,002 | $2,232 | $404 |
| Non-Current Assets | |||||
| PPE Net | 2 | 4 | 7 | 10 | 10 |
| Intangibles | 18,389 | 18,389 | N/A | N/A | N/A |
| TOTAL | $18,391 | $18,393 | $7 | $10 | $10 |
| Total Assets | $19,066 | $18,802 | $1,009 | $2,242 | $414 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 352 | 335 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 2,062 | N/A | 1,782 | 1,440 | 988 |
| Accrued Expenses | 586 | N/A | 617 | 821 | 790 |
| TOTAL | $3,000 | $3,216 | $2,399 | $2,261 | $1,778 |
| Non-Current Liabilities | |||||
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3,000 | $3,216 | $2,399 | $2,261 | $1,778 |
| Shareholders' Equity | |||||
| Common Shares | 180,780 | 179,292 | 161,388 | 161,257 | 158,572 |
| Retained earnings | -216,884 | -215,876 | -214,926 | -213,382 | -212,007 |
| Other shareholders' equity | 3,873 | 3,873 | 3,851 | 4,773 | 5,243 |
| TOTAL | $16,066 | $15,586 | $-1,390 | $-19 | $-1,364 |
| Total Liabilities And Equity | $19,066 | $18,802 | $1,009 | $2,242 | $414 |